Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.76 |
| ▸ | JAK2 | O60674 | 4/20 | 0.76 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.76 |
| ▸ | JAK3 | P52333 | 3/20 | 0.76 |
| ▸ | PLK4 | O00444 | 2/20 | 0.76 |
| ▸ | AURKA | O14965 | 2/20 | 0.76 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.76 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.76 |
| ▸ | INSR | P06213 | 2/20 | 0.76 |
| ▸ | LCK | P06239 | 2/20 | 0.76 |
| ▸ | FES | P07332 | 2/20 | 0.76 |
| ▸ | CSF1R | P07333 | 2/20 | 0.76 |
| ▸ | LYN | P07948 | 2/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | IGF1R | P08069 | 2/20 | 0.76 |
| ▸ | ROS1 | P08922 | 2/20 | 0.76 |
| ▸ | SRC | P12931 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718102 | 1.00 | MET (0.76) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1582052 | 0.94 | MET (0.85) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL18656692 | 0.94 | MET (0.85) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1581843 | 0.94 | MET (0.76) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL3422594 | 0.92 | MET (0.75) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1581764 | 0.92 | MET (0.75) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1582503 | 0.92 | MET (0.75) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL4731086 | 0.92 | MET (0.63) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL18561630 | 0.91 | MET (0.70) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1581486 | 0.91 | MET (0.72) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-107365301-B | Synthesis method of crizotinib and preparation method of intermediate thereof | 上海裕兰生物科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-110559446-A | Targeted therapeutics | 马德里加尔制药公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC | 2019-06-20 | — | — | US | disclosed |
| EP-3471774-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | Oncoselect Therapeutics, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3466416-A2 | A BINDING MOIETY-DRUG CONJUGATE COMPRISING A HSP90 BINDING MOIETY AND A CYTOTOXIC EFFECTOR MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3129064-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015143004-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015134464-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2758387-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | Teligene Ltd. (CN) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013041038-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | TELIGENE LTD. (CN) | 2013-03-28 | — | — | WO | disclosed |
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885JAK2 1085/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885JAK2 1085/4885 |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | TK2, KIT, HCCS | MET 405/4885ALK 2139/4885JAK2 764/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | MET 497/4885ALK 1022/4885JAK2 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.